Pretomanid

Pretomanid is a new chemical entity and a member of a class of compounds known as nitroimidazooxazines. Pretomanid has been clinically evaluated and developed by TB Alliance, a not-for-profit product development partnership dedicated to the discovery and development of new, faster-acting and affordable tuberculosis medicines. Pretomanid is a new chemical entity and a member of a class of compounds known as nitroimidazooxazines. Pretomanid has been clinically evaluated and developed by TB Alliance, a not-for-profit product development partnership dedicated to the discovery and development of new, faster-acting and affordable tuberculosis medicines. Pretomanid is the generic, nonproprietary name for the novel anti-bacterial drug compound formerly called PA-824. Pretomanid is referred to as “Pa” in regimen abbreviations, such as BPaL. The “preto” prefix of the compound’s name honors Pretoria, South Africa, the home of a TB Alliance clinical development office where much of the drug’s development took place. The “manid” suffix is used to group compounds with similar chemical structures.